Paul Hudson, who has just celebrated his five year anniversary as CEO of Sanofi, feels that the firm is well on the way to being regarded as an elite R&D company, an area where it has lagged behind the industry’s research-based heavyweights.
Hudson Holds Reins As Sanofi Makes Strides To Become R&D Powerhouse
“For 20 or 30 years, we were not seen as a scientific leader,” the French major’s CEO tells Scrip. Now, things have started to change with several positive readouts coming out of its immunology portfolio.
More from Leadership
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The UK giant is forecasting peak sales of $5bn plus